PRAMIPEXOLE GxP pramipexole dihydrochloride 0.25 mg tablets blister pack

Pays: Australie

Langue: anglais

Source: Department of Health (Therapeutic Goods Administration)

Ingrédients actifs:

pramipexole dihydrochloride monohydrate, Quantity: 0.25 mg

Disponible depuis:

Arrotex Pharmaceuticals Pty Ltd

DCI (Dénomination commune internationale):

pramipexole dihydrochloride monohydrate

forme pharmaceutique:

Tablet, uncoated

Composition:

Excipient Ingredients: mannitol; pregelatinised maize starch; magnesium stearate; povidone; silicon dioxide

Mode d'administration:

Oral

Unités en paquet:

10, 30, 100

Type d'ordonnance:

(S4) Prescription Only Medicine

indications thérapeutiques:

Pramipexole tablets are indicated for:,-the treatment of signs and symptoms of idiopathic Parkinson's disease. It may be used as monotherapy or in combination with levodopa.

Descriptif du produit:

Visual Identification: White, oval, uncoated tablets debossed with 'CL' and '3' on one side with breakline in between and a breakline on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Statut de autorisation:

Licence status A

Date de l'autorisation:

2014-09-23